A.n.n.

volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts

[A.n.n. @fireflyann]

Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC https://t.co/1FjFjY9AOU

[A.n.n. @fireflyann]

The segment with @drallysonocean starts at near the 1 hour/10 minute mark

[Let's Win Pancreatic Cancer 💜 @letswinpc]

And we have @drallysonocean chatting with @katiecouric about daraxonrasib live on Katie's Substack https://t.co/r6rJ6yhNWd cc @RevMedicines

[Adam Feuerstein ✡️ @adamfeuerstein]

By showing a near-doubling of overall survival already in the second-line setting, daraxonrasib is an example of a “transformative therapy” that makes conducting future, randomized clinical trials more challenging logistically and ethically, Pazdur said.

“If you’re going to do a first-line trial, you have the potential of losing equipoise,” Pazdur said. “People are going to want the drug. Let’s face it, if you have a fatal disease like pancreatic cancer and you are going to die from that disease, you do not want to go on the [control] arm.”

Pazdur proposed alterations to $RVMD's current Ph3 trial in first-line pancreatic cancer that could work to expand the drug's use and get it to patients faster.

My column linked below has more details...

I also spoke w/ RevMed CEO Mark Goldsmith about the same.

[Steve Lee @steveleeyc]

Finally got our first #pancreaticcancer patient onto #daraxonrasib through @RevMedicines @FDAOncology Expanded Access Program. Turned into an unplanned bring-your-daughter-to-work day to get same-day consent to start therapy. Fingers crossed!

[Revolution Medicines @RevMedicines]

#ASCO26 reinforced what we know: RAS-targeted therapies are reshaping cancer treatment. Our Phase 3 RASolute 302 results demonstrate meaningful progress for patients. Excited about what's ahead.

[A.n.n. @fireflyann]

Last day of ASCO..

My typos accumulate!

[A.n.n. @fireflyann]

Great session! With lots of hopeful collrectap cancer research for future ASCOs! Better patient outcomes and clinical guidelines for care

Wonderful way to end #asco26

@ASCO

[Kai-Keen Shiu @KaiKeenShiu]

🙏🙏 @ASCO @Betzabe100 @KristenCiombor We had a wonderful time creating this CRC IO Education Session; case debate/voting/Q+A too! Thank to Stacey Cohen and our moderator, Chris Lieu a ASCO-FASCO pro! Thank you ++ to the ASCO AV team who were so helpful+patient with us! 🙏🙏🤝🤝

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

The work is far from finished. As excitement builds, researchers are already focused on the next questions: how to achieve more durable responses and understand resistance to help further improve outcomes for patients—questions at the heart of our collaborative daraxonrasib study with Revolution Medicines, which is designed to understand not just whether this therapy works, but how and why it works in patients.

[Let's Win Pancreatic Cancer 💜 @letswinpc]

Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://t.co/cUA7KU8msU

[Samuel Hume @DrSamuelBHume]

4. What's next for Daraxonrasib? More trials!

1st line in metastatic pancreatic cancer, and after surgery in resectable disease; in lung cancer; and in other solid cancers, like colorectal

[Dr. Nina Niu Sanford @NiuSanford]

MIRACLE-2: RT to primary/mets -> chemo + tislelizumab in MSS unresectable met rectal ca (N=50): 68% ORR & median OS 23 mo.

Early, single-arm data, but ~1 in 5 pts reached NED.

Suggests RT + systemic + PD1 blockade could overcome immune resistance in MSS mCRC. #ASCO26 @OncoAlert

[Kate Sears @MedwatchKate]

Top Post at #ASCO26 in #ColorectalCancer:

[PanCAN @PanCAN]

PanCAN's Chief Scientific and Medical Officer, Dr. @ABerkenblit, shares, "I know that in the years to come, we'll look back on this year's #ASCO26 meeting as marking the beginning of a new era for patients with pancreatic cancer. As a long-standing American Society of Clinical Oncology (ASCO) member, it was a privilege this year to attend alongside my colleagues from Pancreatic Cancer Action Network, knowing the pivotal role PanCAN played to get us to this historic moment, and that the community is looking to PanCAN to help us all make good on the promise that RAS therapies hold for patients with pancreatic cancer.

Unprecedented indeed are the Phase 3 data for #daraxonrasib, a RAS-targeted therapy developed by Revolution Medicines and presented by Dr. Brian Wolpin. These highly anticipated data were received with wild enthusiasm — a standing ovation! — from the ASCO community. Overall survival and progression-free survival were ~doubled, and overall response rate was ~tripled with daraxonrasib compared with chemotherapy in patients with previously treated metastatic pancreatic cancer, with all subgroups benefiting. Importantly, quality of life and pain were improved, so that patients not only live longer, but also feel better — just what we want from new therapies. Optimal management of side effects, including rash and mouth sores, is paramount to maximize the benefit — and PanCAN Patient Services is ready to embrace the educational needs!"

Learn more about the additional data released on daraxonrasib and this significant advance for #pancreaticcancer treatment at 🔗 https://t.co/hzw7yln7wo.

[Nyah Phengsitthy @nyahphengsitthy]

1/ Groups to meet with FDA this afternoon:

Cure Sanfilippo Foundation
Cystic Fibrosis Foundation
EveryLife Foundation for Rare Diseases
Foundation for Angelman Syndrome Therapeutics
Friedreich's Ataxia Research Alliance
Friends of Cancer Research
Global Genes
Haystack Project

[A.n.n. @fireflyann]

@DrSukeshiArora @RevMedicines The first shipments went out last week.

The paperwork is streamlined through cancer centers.

I dont know how it is/isnt working for community oncologists.

Great question for @RevMedicines

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

#ASCO26 | Abstr 3510
CRDF-004: rPh2 Onvansertib + Chemo + Bev in 1L RAS-mutated mCRC
Promising ORR and PFS HR, but results should be interpreted with caution due to the small sample size. Ph3 is planned.
@ASCO @OncoAlert

[Ivy Riano, M.D. @IvyLorena_Md]

Posing with the Future Member of @ASCO #ASCO26

Career plans still under review, but the badge is official 🤣

Thank you @ASCO for the cute badge!

[Arndt Vogel @ArndtVogel]

Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5- targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases
#ASCO26
👉high response rates in heavily pretreated patients
🧐More data on CAR-T cells..
@myesmo @ASCO

[KRAS Kickers @KRASKickers]

@kathmacphail @DrHBurstein also -
the distinction between a "standing ovation"
and

"an interrupting standing ovation"

Also - great point in chat re need for patients to understand more of these concepts.

We're trying...
4,192 members (pts & carepartners) in our main FB group

[KRAS Kickers @KRASKickers]

Agree with @kathmacphail - that was a great conversation!

The application of daraxonrasib IN THE CLINIC will provide so much info for clinicians to move forward.

@DrHBurstein's important point about whether enrollment in a first line trial is even possible now (loss of equipoise).

https://t.co/GEqjXrt7AG

[A.n.n. @fireflyann]

Phenomenal discussion

#asco26... before and beyond

@endpts
@kevansf

[KRAS Kickers @KRASKickers]

Starting now....
@endpts at #ASCO26

particularly interesting in "all things KRAS"!